MEDIUM confidence: 100% data completeness, but the composite (54) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0— | $0n/m | $51Mn/m | $291M+473.0% | $389M+33.9% |
| EPS (dil.) | $-3.13— | $-5.49n/m | $0.39n/m | $3.00+669.2% | $6.84+128.0% |
| Free Cash Flow | -$116M— | -$154Mn/m | -$101Mn/m | $119Mn/m | $189M+58.5% |
| Gross Margin | — | — | 93.9% | 93.1%-0.8pp | 92.6%-0.5pp |
| Operating Margin | — | — | -216.4% | 22.6%+239.0pp | 41.5%+18.8pp |
| Net Margin | — | — | 21.6% | 30.7%+9.1pp | 52.6%+21.9pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $331 (last qtr, 2 analysts) → $361 (last mo, 1) (+9.2%).
Buy-rated share 91% → 91% over ~3 months (+0pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| May 2026 | $1.45 | $1.83 | +26.2% |
| Feb 2026 | $1.62 | $1.70 | +4.9% |
| Nov 2025 | $1.12 | $2.66 | +137.5% |
| Aug 2025 | $1.08 | $1.29 | +19.4% |
| May 2025 | $1.38 | $1.20 | -13.0% |
| Feb 2025 | $1.29 | $1.52 | +17.8% |
| Nov 2024 | $0.90 | $0.91 | +1.1% |
| Aug 2024 | $0.50 | $0.86 | +72.0% |
Net insider -$29.3M over 180 days (0 open-market buys, 45 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
The QScore of 54 for Krystal Biotech indicates a moderately positive outlook, driven by strong momentum and growth scores of 73 and 55, respectively, with notable revenue growth of 33.9% and a 12-month return of 161.2%. However, the stock's value score is relatively low at 25, reflecting a high P/E of 48.0 and P/B of 8.5. The short-term score of 60 diverges from the long-term score of 49, suggesting a recent surge in performance, with the stock exhibiting strong momentum and trading at a premium.